Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)

CAPS Rating: 3 out of 5

A development-stage biopharmaceutical company dedicated to the discovery, development and eventual commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders.


Player Avatar zzlangerhans (99.85) Submitted: 7/2/2011 1:40:20 AM : Outperform Start Price: $8.40 CYCC Score: -59.81

With the dilutive financing today, all the pieces are in place for Cyclacel to rebound in the second half:

1. Bad news out of the way. Selciclib failed in the APPRAISE trial and will no longer weigh on the share price.

2. Major up/down catalysts approaching. The SEAMLESS phase III trial of sapacitabine in elderly AML began in January and will determine the future of the company, or lack thereof. Topline data for sapacitabine in NSCLC is also expected later this year.

3. Financially stable through catalysts. About 35M in cash reserves after today's financing and a burn rate of about 5M/quarter.

4. New 18 month low today.

Cyclacel could certainly go lower since catalysts are still many months if not more than a year away. But I'll take my CAPS position here as this could become a GBMB play if it continues to drop below 1.

Report this Post 4 Replies
Member Avatar zzlangerhans (99.85) Submitted: 7/25/2011 2:24:11 PM
Recs: 1

Bought 10000 shares today at 1.18 for the GBMB account.

Member Avatar str790 (70.62) Submitted: 9/26/2011 10:17:53 AM
Recs: 1

Any new concern with this stock, or are we just seeing irrational dumping due to the delisting threat?

Member Avatar Mega (99.97) Submitted: 3/11/2012 3:12:19 PM
Recs: 0

The burn rate now seems to be much higher than $5M / quarter.

Member Avatar zzlangerhans (99.85) Submitted: 10/15/2012 12:56:26 PM
Recs: 0

Sold all shares today at 7.68 (interim 7:1 reverse split) for a $850 GBMB loss. Disappointing, but considering I was down more than $7000 at one point I'm pleased.

Featured Broker Partners